Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe
Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR)...
Ausführliche Beschreibung
Autor*in: |
Anouk J. M. M. Braspenning [verfasserIn] Sahaya Glingston Rajakani [verfasserIn] Adwoa Sey [verfasserIn] Mariem El Bounja [verfasserIn] Christine Lammens [verfasserIn] Youri Glupczynski [verfasserIn] Surbhi Malhotra-Kumar [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2024 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Antibiotics - MDPI AG, 2013, 13(2024), 3, p 281 |
---|---|
Übergeordnetes Werk: |
volume:13 ; year:2024 ; number:3, p 281 |
Links: |
---|
DOI / URN: |
10.3390/antibiotics13030281 |
---|
Katalog-ID: |
DOAJ100882528 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ100882528 | ||
003 | DE-627 | ||
005 | 20240414131754.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240414s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/antibiotics13030281 |2 doi | |
035 | |a (DE-627)DOAJ100882528 | ||
035 | |a (DE-599)DOAJ7310b34ebc3b4a29905935fe844a51ab | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RM1-950 | |
100 | 0 | |a Anouk J. M. M. Braspenning |e verfasserin |4 aut | |
245 | 1 | 0 | |a Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens. | ||
650 | 4 | |a colistin resistance | |
650 | 4 | |a mechanisms | |
650 | 4 | |a mgrB | |
650 | 4 | |a population analysis profiling | |
650 | 4 | |a whole-genome sequencing | |
653 | 0 | |a Therapeutics. Pharmacology | |
700 | 0 | |a Sahaya Glingston Rajakani |e verfasserin |4 aut | |
700 | 0 | |a Adwoa Sey |e verfasserin |4 aut | |
700 | 0 | |a Mariem El Bounja |e verfasserin |4 aut | |
700 | 0 | |a Christine Lammens |e verfasserin |4 aut | |
700 | 0 | |a Youri Glupczynski |e verfasserin |4 aut | |
700 | 0 | |a Surbhi Malhotra-Kumar |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Antibiotics |d MDPI AG, 2013 |g 13(2024), 3, p 281 |w (DE-627)726120596 |w (DE-600)2681345-2 |x 20796382 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2024 |g number:3, p 281 |
856 | 4 | 0 | |u https://doi.org/10.3390/antibiotics13030281 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/7310b34ebc3b4a29905935fe844a51ab |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/2079-6382/13/3/281 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2079-6382 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 13 |j 2024 |e 3, p 281 |
author_variant |
a j m m b ajmmb s g r sgr a s as m e b meb c l cl y g yg s m k smk |
---|---|
matchkey_str |
article:20796382:2024----::sesetfoitneeoeitnemnmlirgeitnilbilanuoieioaef |
hierarchy_sort_str |
2024 |
callnumber-subject-code |
RM |
publishDate |
2024 |
allfields |
10.3390/antibiotics13030281 doi (DE-627)DOAJ100882528 (DE-599)DOAJ7310b34ebc3b4a29905935fe844a51ab DE-627 ger DE-627 rakwb eng RM1-950 Anouk J. M. M. Braspenning verfasserin aut Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens. colistin resistance mechanisms mgrB population analysis profiling whole-genome sequencing Therapeutics. Pharmacology Sahaya Glingston Rajakani verfasserin aut Adwoa Sey verfasserin aut Mariem El Bounja verfasserin aut Christine Lammens verfasserin aut Youri Glupczynski verfasserin aut Surbhi Malhotra-Kumar verfasserin aut In Antibiotics MDPI AG, 2013 13(2024), 3, p 281 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:13 year:2024 number:3, p 281 https://doi.org/10.3390/antibiotics13030281 kostenfrei https://doaj.org/article/7310b34ebc3b4a29905935fe844a51ab kostenfrei https://www.mdpi.com/2079-6382/13/3/281 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2024 3, p 281 |
spelling |
10.3390/antibiotics13030281 doi (DE-627)DOAJ100882528 (DE-599)DOAJ7310b34ebc3b4a29905935fe844a51ab DE-627 ger DE-627 rakwb eng RM1-950 Anouk J. M. M. Braspenning verfasserin aut Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens. colistin resistance mechanisms mgrB population analysis profiling whole-genome sequencing Therapeutics. Pharmacology Sahaya Glingston Rajakani verfasserin aut Adwoa Sey verfasserin aut Mariem El Bounja verfasserin aut Christine Lammens verfasserin aut Youri Glupczynski verfasserin aut Surbhi Malhotra-Kumar verfasserin aut In Antibiotics MDPI AG, 2013 13(2024), 3, p 281 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:13 year:2024 number:3, p 281 https://doi.org/10.3390/antibiotics13030281 kostenfrei https://doaj.org/article/7310b34ebc3b4a29905935fe844a51ab kostenfrei https://www.mdpi.com/2079-6382/13/3/281 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2024 3, p 281 |
allfields_unstemmed |
10.3390/antibiotics13030281 doi (DE-627)DOAJ100882528 (DE-599)DOAJ7310b34ebc3b4a29905935fe844a51ab DE-627 ger DE-627 rakwb eng RM1-950 Anouk J. M. M. Braspenning verfasserin aut Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens. colistin resistance mechanisms mgrB population analysis profiling whole-genome sequencing Therapeutics. Pharmacology Sahaya Glingston Rajakani verfasserin aut Adwoa Sey verfasserin aut Mariem El Bounja verfasserin aut Christine Lammens verfasserin aut Youri Glupczynski verfasserin aut Surbhi Malhotra-Kumar verfasserin aut In Antibiotics MDPI AG, 2013 13(2024), 3, p 281 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:13 year:2024 number:3, p 281 https://doi.org/10.3390/antibiotics13030281 kostenfrei https://doaj.org/article/7310b34ebc3b4a29905935fe844a51ab kostenfrei https://www.mdpi.com/2079-6382/13/3/281 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2024 3, p 281 |
allfieldsGer |
10.3390/antibiotics13030281 doi (DE-627)DOAJ100882528 (DE-599)DOAJ7310b34ebc3b4a29905935fe844a51ab DE-627 ger DE-627 rakwb eng RM1-950 Anouk J. M. M. Braspenning verfasserin aut Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens. colistin resistance mechanisms mgrB population analysis profiling whole-genome sequencing Therapeutics. Pharmacology Sahaya Glingston Rajakani verfasserin aut Adwoa Sey verfasserin aut Mariem El Bounja verfasserin aut Christine Lammens verfasserin aut Youri Glupczynski verfasserin aut Surbhi Malhotra-Kumar verfasserin aut In Antibiotics MDPI AG, 2013 13(2024), 3, p 281 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:13 year:2024 number:3, p 281 https://doi.org/10.3390/antibiotics13030281 kostenfrei https://doaj.org/article/7310b34ebc3b4a29905935fe844a51ab kostenfrei https://www.mdpi.com/2079-6382/13/3/281 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2024 3, p 281 |
allfieldsSound |
10.3390/antibiotics13030281 doi (DE-627)DOAJ100882528 (DE-599)DOAJ7310b34ebc3b4a29905935fe844a51ab DE-627 ger DE-627 rakwb eng RM1-950 Anouk J. M. M. Braspenning verfasserin aut Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens. colistin resistance mechanisms mgrB population analysis profiling whole-genome sequencing Therapeutics. Pharmacology Sahaya Glingston Rajakani verfasserin aut Adwoa Sey verfasserin aut Mariem El Bounja verfasserin aut Christine Lammens verfasserin aut Youri Glupczynski verfasserin aut Surbhi Malhotra-Kumar verfasserin aut In Antibiotics MDPI AG, 2013 13(2024), 3, p 281 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:13 year:2024 number:3, p 281 https://doi.org/10.3390/antibiotics13030281 kostenfrei https://doaj.org/article/7310b34ebc3b4a29905935fe844a51ab kostenfrei https://www.mdpi.com/2079-6382/13/3/281 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2024 3, p 281 |
language |
English |
source |
In Antibiotics 13(2024), 3, p 281 volume:13 year:2024 number:3, p 281 |
sourceStr |
In Antibiotics 13(2024), 3, p 281 volume:13 year:2024 number:3, p 281 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
colistin resistance mechanisms mgrB population analysis profiling whole-genome sequencing Therapeutics. Pharmacology |
isfreeaccess_bool |
true |
container_title |
Antibiotics |
authorswithroles_txt_mv |
Anouk J. M. M. Braspenning @@aut@@ Sahaya Glingston Rajakani @@aut@@ Adwoa Sey @@aut@@ Mariem El Bounja @@aut@@ Christine Lammens @@aut@@ Youri Glupczynski @@aut@@ Surbhi Malhotra-Kumar @@aut@@ |
publishDateDaySort_date |
2024-01-01T00:00:00Z |
hierarchy_top_id |
726120596 |
id |
DOAJ100882528 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ100882528</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414131754.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics13030281</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ100882528</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7310b34ebc3b4a29905935fe844a51ab</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anouk J. M. M. Braspenning</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colistin resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mechanisms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mgrB</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">population analysis profiling</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">whole-genome sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sahaya Glingston Rajakani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adwoa Sey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mariem El Bounja</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christine Lammens</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Youri Glupczynski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Surbhi Malhotra-Kumar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">13(2024), 3, p 281</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:3, p 281</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics13030281</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7310b34ebc3b4a29905935fe844a51ab</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/13/3/281</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2024</subfield><subfield code="e">3, p 281</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Anouk J. M. M. Braspenning |
spellingShingle |
Anouk J. M. M. Braspenning misc RM1-950 misc colistin resistance misc mechanisms misc mgrB misc population analysis profiling misc whole-genome sequencing misc Therapeutics. Pharmacology Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe |
authorStr |
Anouk J. M. M. Braspenning |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)726120596 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RM1-950 |
illustrated |
Not Illustrated |
issn |
20796382 |
topic_title |
RM1-950 Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe colistin resistance mechanisms mgrB population analysis profiling whole-genome sequencing |
topic |
misc RM1-950 misc colistin resistance misc mechanisms misc mgrB misc population analysis profiling misc whole-genome sequencing misc Therapeutics. Pharmacology |
topic_unstemmed |
misc RM1-950 misc colistin resistance misc mechanisms misc mgrB misc population analysis profiling misc whole-genome sequencing misc Therapeutics. Pharmacology |
topic_browse |
misc RM1-950 misc colistin resistance misc mechanisms misc mgrB misc population analysis profiling misc whole-genome sequencing misc Therapeutics. Pharmacology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Antibiotics |
hierarchy_parent_id |
726120596 |
hierarchy_top_title |
Antibiotics |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)726120596 (DE-600)2681345-2 |
title |
Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe |
ctrlnum |
(DE-627)DOAJ100882528 (DE-599)DOAJ7310b34ebc3b4a29905935fe844a51ab |
title_full |
Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe |
author_sort |
Anouk J. M. M. Braspenning |
journal |
Antibiotics |
journalStr |
Antibiotics |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2024 |
contenttype_str_mv |
txt |
author_browse |
Anouk J. M. M. Braspenning Sahaya Glingston Rajakani Adwoa Sey Mariem El Bounja Christine Lammens Youri Glupczynski Surbhi Malhotra-Kumar |
container_volume |
13 |
class |
RM1-950 |
format_se |
Elektronische Aufsätze |
author-letter |
Anouk J. M. M. Braspenning |
doi_str_mv |
10.3390/antibiotics13030281 |
author2-role |
verfasserin |
title_sort |
assessment of colistin heteroresistance among multidrug-resistant <i<klebsiella pneumoniae</i< isolated from intensive care patients in europe |
callnumber |
RM1-950 |
title_auth |
Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe |
abstract |
Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens. |
abstractGer |
Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens. |
abstract_unstemmed |
Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3, p 281 |
title_short |
Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe |
url |
https://doi.org/10.3390/antibiotics13030281 https://doaj.org/article/7310b34ebc3b4a29905935fe844a51ab https://www.mdpi.com/2079-6382/13/3/281 https://doaj.org/toc/2079-6382 |
remote_bool |
true |
author2 |
Sahaya Glingston Rajakani Adwoa Sey Mariem El Bounja Christine Lammens Youri Glupczynski Surbhi Malhotra-Kumar |
author2Str |
Sahaya Glingston Rajakani Adwoa Sey Mariem El Bounja Christine Lammens Youri Glupczynski Surbhi Malhotra-Kumar |
ppnlink |
726120596 |
callnumber-subject |
RM - Therapeutics and Pharmacology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/antibiotics13030281 |
callnumber-a |
RM1-950 |
up_date |
2024-07-03T17:13:37.215Z |
_version_ |
1803578839889084416 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ100882528</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414131754.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics13030281</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ100882528</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7310b34ebc3b4a29905935fe844a51ab</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anouk J. M. M. Braspenning</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Assessment of Colistin Heteroresistance among Multidrug-Resistant <i<Klebsiella pneumoniae</i< Isolated from Intensive Care Patients in Europe</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR) <i<K. pneumoniae</i< are prevalent and empiric use of colistin might lead to treatment failures. This study aimed to assess the frequency of occurrence of colistin HR (CHR) among (MDR) <i<K. pneumoniae</i< (<i<n</i< = 676) isolated from patients hospitalized in 13 intensive care units (ICUs) in six European countries in a clinical trial assessing the impact of decolonization strategies. All isolates were whole-genome-sequenced and studied for in vitro colistin susceptibility. The majority were colistin-susceptible (CS) (<i<n</i< = 597, MIC ≤ 2 µg/mL), and 79 were fully colistin-resistant (CR) (MIC < 2 µg/mL). A total of 288 CS isolates were randomly selected for population analysis profiling (PAP) to assess CHR prevalence. CHR was detected in 108/288 CS <i<K. pneumoniae</i<. No significant association was found between the occurrence of CHR and country, MIC-value, K-antigen type, and O-antigen type. Overall, 92% (617/671) of the <i<K. pneumoniae</i< were MDR with high prevalence among CS (91%, 539/592) and CR (98.7%, 78/79) isolates. In contrast, the proportion of carbapenemase-producing <i<K. pneumoniae</i< (CP-Kpn) was higher among CR (72.2%, 57/79) than CS isolates (29.3%, 174/594). The proportions of MDR and CP-Kpn were similar among CHR (MDR: 85%, 91/107; CP-Kpn: 29.9%, 32/107) and selected CS isolates (MDR: 84.7%, 244/288; CP-Kpn: 28.1%, 80/285). WGS analysis of PAP isolates showed diverse insertion elements in <i<mgrB</i< or even among technical replicates underscoring the stochasticity of the CHR phenotype. CHR isolates showed high sequence type (ST) diversity (Simpson’s diversity index, SDI: 0.97, in 52 of the 85 STs tested). CR (SDI: 0.85) isolates were highly associated with specific STs (ST101, ST147, ST258/ST512, <i<p</i< ≤ 0.003). The widespread nature of CHR among MDR <i<K. pneumoniae</i< in our study urge the development of rapid HR detection methods to inform on the need for combination regimens.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colistin resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mechanisms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mgrB</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">population analysis profiling</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">whole-genome sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sahaya Glingston Rajakani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adwoa Sey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mariem El Bounja</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christine Lammens</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Youri Glupczynski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Surbhi Malhotra-Kumar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">13(2024), 3, p 281</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:3, p 281</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics13030281</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7310b34ebc3b4a29905935fe844a51ab</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/13/3/281</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2024</subfield><subfield code="e">3, p 281</subfield></datafield></record></collection>
|
score |
7.39931 |